Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 14/20 | 0.77 |
| ▸ | PDE8A | O60658 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6910848 | 1.00 | PDE8B (0.77) | PDE8BPDE8AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6909177 | 0.87 | PDE8B (0.72) | PDE8BPDE8AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6909895 | 0.87 | PDE8B (0.77) | PDE8BPDE8AALDH1A1LMNAADORA3 | |
| SCHEMBL6910951 | 0.87 | PDE8B (1.00) | PDE8BPDE8A | |
| SCHEMBL6909462 | 0.87 | PDE8B (1.00) | PDE8BPDE8A | |
| SCHEMBL6910946 | 0.87 | PDE8B (1.00) | PDE8BPDE8A | |
| SCHEMBL6909564 | 0.87 | PDE8B (1.00) | PDE8BPDE8AALDH1A1 | |
| SCHEMBL6910646 | 0.87 | PDE8B (0.69) | PDE8BPDE8AALDH1A1LMNA | |
| SCHEMBL6910920 | 0.86 | PDE8B (0.77) | PDE8BPDE8A | |
| SCHEMBL6910554 | 0.84 | PDE8B (0.71) | PDE8BPDE8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011058478-A1 | SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |